Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Zhejiang Hisun Animal Health Products, received approval from China's Ministry of Agriculture and Rural Affairs for veterinary drug cefpodoxime proxetil chewable tablets.
The approval is valid until June 17, 2029, according to a Tuesday disclosure on the Shanghai Stock Exchange
The drug is suitable for the treatment of canine skin infections.
Shares of the company slipped less than 3% at the close.
Price (RMB): ¥7.17, Change: ¥-0.20, Percent Change: -2.71%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments